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ABSTRACT
OBJECTIVE
To investigate whether symptomatic treatment with 
non-steroidal anti-inflammatory drugs (NSAIDs) 
is non-inferior to antibiotics in the treatment of 
uncomplicated lower urinary tract infection (UTI) 
in women, thus offering an opportunity to reduce 
antibiotic use in ambulatory care.
DESIGN
Randomised, double blind, non-inferiority trial.
SETTING
17 general practices in Switzerland.
PARTICIPANTS
253 women with uncomplicated lower UTI were 
randomly assigned 1:1 to symptomatic treatment with 
the NSAID diclofenac (n=133) or antibiotic treatment 
with norfloxacin (n=120). The randomisation 
sequence was computer generated, stratified by 
practice, blocked, and concealed using sealed, 
sequentially numbered drug containers.
MAIN OUTCOME MEASURES
The primary outcome was resolution of symptoms at 
day 3 (72 hours after randomisation and 12 hours 
after intake of the last study drug). The prespecified 
principal secondary outcome was the use of any 
antibiotic (including norfloxacin and fosfomycin as 
trial drugs) up to day 30. Analysis was by intention to 
treat.
RESULTS
72/133 (54%) women assigned to diclofenac and 
96/120 (80%) assigned to norfloxacin experienced 
symptom resolution at day 3 (risk difference 27%, 
95% confidence interval 15% to 38%, P=0.98 for 
non-inferiority, P<0.001 for superiority). The median 
time until resolution of symptoms was four days in 
the diclofenac group and two days in the norfloxacin 
group. A total of 82 (62%) women in the diclofenac 
group and 118 (98%) in the norfloxacin group used 
antibiotics up to day 30 (risk difference 37%, 28% 
to 46%, P<0.001 for superiority). Six women in the 
diclofenac group (5%) but none in the norfloxacin 
group received a clinical diagnosis of pyelonephritis 
(P=0.03).
CONCLUSION
Diclofenac is inferior to norfloxacin for symptom 
relief of UTI and is likely to be associated with an 
increased risk of pyelonephritis, even though it 
reduces antibiotic use in women with uncomplicated 
lower UTI.
TRIAL REGISTRATION
ClinicalTrials.gov NCT01039545.
Introduction
Antimicrobial stewardship aims at reducing antibiotic 
resistance by optimising or decreasing antibiotic use,1 
which includes the prevention of antibiotic treatment 
in cases of viral infections, tailored prescription of 
narrow spectrum antibiotics, shortening the course 
of treatment, and deferring treatment for low risk 
bacterial infections. Urinary tract infection (UTI) 
is one of the most common bacterial infections in 
adults, affecting considerably more women than 
men.2 Approximately half of women have at least one 
UTI in their lifetime, and 20-30% have two or more.3 
Antibiotic prescriptions for UTI account for 10-20% of 
all antibiotic prescriptions in ambulatory care and are 
second only to antibiotic prescriptions for respiratory 
tract infections.4 5 Reducing antibiotic prescriptions 
for UTI could potentially decrease the risk of antibiotic 
resistance. Therefore, the benefit of antibiotic 
treatment needs to be weighed against the potential 
for adverse effects, at both the individual level (adverse 
drug reactions) and the population level (as a driver of 
antibiotic resistance).
Symptoms of UTI may arise from local increases 
in pro-inflammatory factors such as prostaglandins, 
and non-steroidal anti-inflammatory drugs (NSAIDs) 
may be useful in alleviating symptoms.6-8 A small 
randomised pilot trial, which compared the NSAID 
ibuprofen with the antibiotic ciprofloxacin in 80 
women with uncomplicated lower UTI, concluded 
that symptomatic treatment with NSAIDs may be non-
inferior to antibiotics, but suggested confirmation in 
a larger trial.9 Two adequately powered randomised 
double blind trials were therefore initiated 
simultaneously in February 2012 in Germany and 
Switzerland. Results of the German trial, which 
compared ibuprofen with fosfomycin in 494 women, 
were recently published.10 Here we report results 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Uncomplicated urinary tract infection is a common reason for antibiotic 
prescription in ambulatory care even though it is often benign and self limiting
Reducing antibiotic usage is important to combat increasing rates of antibiotic 
resistance
WhAT ThIS STudy AddS
Symptomatic treatment of lower urinary tract infections prolongs symptom 
duration and is likely to be associated with an increased risk of pyelonephritis
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of the Swiss trial, which compared diclofenac with 
norfloxacin in women with uncomplicated lower UTI.
Methods
Study design
This randomised controlled trial with blinding of 
patients and assessors was conducted in 17 general 
practices in the German speaking part of Switzerland. 
All women provided written informed consent.
Patients, randomisation, and treatment
Women aged 18 to 70 years, who visited their general 
practitioner because of one or more symptoms or 
signs typical of acute lower UTI (dysuria, frequency, 
macrohaematuria, cloudy or smelly urine) or self 
diagnosed symptomatic cystitis were eligible if their 
urine dipstick was positive for nitrite or leucocytes, 
or both. We excluded pregnant women and women 
with clinical signs of upper UTI such as fever (axillary 
body temperature >38°C), costovertebral pain or 
tenderness, rigors, and nausea or vomiting. We also 
excluded women with known or suspected anatomical 
or functional abnormality of the urinary tract and 
comorbidities such as diabetes mellitus, active 
gastric or duodenal ulcer disease or gastrointestinal 
bleeding, inflammatory bowel disease, severe liver 
dysfunction (liver cirrhosis and ascites), coagulopathy 
(including treatment with coumarine derivates), renal 
insufficiency grade 3 or higher (calculated glomerular 
filtration rate <60 mL/min), known congestive heart 
failure (New York Heart Association (NYHA) III or 
higher), psychiatric illness or dementia, inability to 
communicate in German or French, and any other 
serious comorbidity as judged by the treating doctor. 
In addition we excluded women with documented 
immunosuppression (eg, prednisone equivalent >10 
mg/day for >14 days, chemotherapy, radiotherapy, 
immunomodulators, HIV infection, neutropenia) or 
hypersensitivity to one of the study drugs or a history 
of asthma, urticaria, or hypersensitivity-like reactions 
after consumption of salicylic acid or other non-
steroidal anti-inflammatory drugs, as well as women 
with vaginal symptoms (discharge, irritation), bladder 
catheter in situ or during the past 30 days, recurrent 
UTI (more than three infections during the past 12 
months), antibiotic treatment during the past four 
weeks, or UTI symptoms present for more than seven 
days before visiting the doctor.
Women were randomly allocated in a 1:1 
ratio to diclofenac or norfloxacin treatment. The 
randomisation sequence was computer generated, 
stratified by practice, and blocked with randomly 
varying block sizes of 4 and 6. Allocation was 
concealed with sealed, sequentially numbered opaque 
drug containers of identical appearance that contained 
opaque hard gelatine capsules of identical size and 
colour. Women allocated to diclofenac received 
capsules containing 75 mg diclofenac retard for three 
days (Olfen-75 duo release; Mepha Pharma, Basel, 
Switzerland) and women allocated to norfloxacin 
received capsules containing 400 mg norfloxacin for 
three days (Norfloxacin-Teva; Teva Pharma, Tel Aviv, 
Israel; or Norflocin-Mepha; Lactab, Mepha Pharma, 
Basel, Switzerland from October 2013 onwards 
owing to delivery restrictions). We chose norfloxacin 
because of the high susceptibility rates in Switzerland 
and diclofenac because of its identical frequency 
of being administered, which facilitated patient 
blinding. Women started treatment immediately after 
randomisation on day 0 and were advised to take two 
capsules each day: one in the morning and one in the 
evening. All women were given a single open label 
package of fosfomycin (Monuril; Zambon, Cadempino, 
Switzerland) to be taken as rescue antibiotic (3 g dose) 
after completion of the study drug on day 3 at their 
discretion, if symptoms persisted.
Procedures and outcomes
The prespecified primary outcome was symptom 
resolution on day 3 (72 hours after randomisation and 
12 hours after intake of the last study drug). In the 
absence of antimicrobial resistance, the mean duration 
of symptoms in women with uncomplicated UTIs 
treated with antibiotics is three days.11 The self report 
questionnaire used to ascertain severity of symptoms was 
developed based on questionnaires described by Clayson 
et al12 and Little et al.13 Women rated the severity of five 
UTI symptoms (dysuria, frequency, urgency, abdominal 
pain when passing urine, pain or tenderness in the lower 
back or loin) daily from days 0 (randomisation) to 10 in 
a diary and on day 30 by telephone interview on a Likert 
scale from 0 to 6, with their composite score ranging 
from 0 to 30. Symptom resolution was defined as 2 or 
less points (slight, very slight, or no problems) on all five 
components.12 14 15 Complete absence of symptoms was 
defined as 0 points on all components. When the trial 
was registered on ClinicalTrials.gov (NCT01039545), 
the day of randomisation was defined as day 1, but 
for the purposes of this report it was defined as day 
0. Therefore day 4, described as the time point of the 
primary outcome on ClinicalTrials.gov, corresponds 
to day 3 in this report. The prespecified principal 
secondary outcome was the use of any antibiotic 
(including norfloxacin and fosfomycin as trial drugs) up 
to day 30. The remaining prespecified outcomes were 
resolution of symptoms on day 7; complete absence 
of symptoms on days 3 and 7; use of rescue antibiotic 
(fosfomycin) up to day 3; negative urinary culture result 
on day 10; reconsultations because of UTI up to day 
30; mean composite symptom score on days 3, 7, and 
30; time until resolution of symptoms; adverse events; 
serious adverse events; European quality of life (EQ-5D) 
health state and visual analogue scale on day 3; working 
days lost; and overall satisfaction with management 
of the UTI. Additional time points analysed, which 
were not prespecified in the protocol but specified 
before statistical analysis, included days 10 and 30 for 
resolution and complete absence of symptoms, day 10 
for symptom scores, day 3 for use of any antibiotic, and 
day 30 for use of rescue antibiotics. 
The treating doctor and an independent, blinded 
interviewer carried out telephone interviews on days 
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10 and 30, respectively, to assess serious adverse 
events, adverse events of grade 3 or more severity, 
any additional unplanned medical visits, including 
telephone contacts, and co-medications. The clinical 
diagnosis of pyelonephritis required the occurrence 
of loin pain and fever, leading to an unplanned 
outpatient visit. Mid-stream urinary samples obtained 
on days 0 and 10 were processed according to standard 
laboratory procedures, using a cut-off of ≥103 colony 
forming units per millilitre for a urinary culture to be 
considered positive16; mixed flora with no predominant 
microorganism, Lactobacilli or Streptococcus 
viridans group were considered a negative result. 
The supplementary appendix provides details of the 
baseline assessments, diaries, and scores used.
Statistical analysis
We originally planned to recruit 400 women, but 
recruitment was slow and financial constraints led us 
to decide in June 2014 to stop patient recruitment by 
December 2014, when an expected 260 women would 
be included. The decision was made without inspecting 
the data and after repeating the power analysis based 
on a normal approximation test of proportions,17 
which was less conservative than the simulation based 
approach originally used. With the original assumption 
of 70% of women reaching symptom resolution up to 
day 3 in both groups and the original, prespecified 
non-inferiority margin of 15% on a risk difference 
scale, the projected sample size of 260 women would 
yield a power of 84% to detect non-inferiority at a 
one sided type I error of 5%. A systematic review and 
meta-analysis by Falagas et al18 suggested symptom 
resolution in approximately 25% of women with UTI 
receiving placebo and in approximately 60% of women 
receiving antibiotics. The selected non-inferiority 
margin of 15% was less than half of the pooled risk 
difference between antibiotics and placebo of 35%.
The primary outcome was evaluated using a risk 
difference with a corresponding two sided 95% 
confidence interval, a one sided normal approximation 
test for non-inferiority, and a two sided χ2 test for 
superiority. We compared secondary outcomes using 
conventional two sided P values for superiority and 
corresponding two sided 95% confidence intervals. 
We used risk differences with χ2 tests for binary data, 
Poisson regression with robust standard errors for 
counts, and linear regression with robust standard 
errors for continuous data. Kaplan-Meier curves 
accompanied by hazard ratios from Cox models were 
used to analyse time to definite symptom resolution 
and time to antibiotic use. Women were considered to 
have reached definite symptom resolution in the time-
to-event analysis if they reached ≤2 points (slight, 
very slight, or no problems) on all five components 
of the symptom severity score and did not report a 
subsequent flare-up. All women were included in the 
analysis in the groups to which they were originally 
allocated (intention to treat analysis), with missing 
values accounted for by multiple imputation (see 
supplementary appendix and supplementary table 1).
We performed prespecified subgroup analyses of the 
primary outcome accompanied by Mantel-Haenszel 
tests for interaction by age (<45 v ≥45 years), symptom 
severity at baseline (≤20 v >20), symptom duration (≤3 
v >3 days), and presence of a positive urinary culture 
result at baseline; post hoc subgroup analyses were 
performed for urine leucocytes (≤++ v >++) and the 
presence of norfloxacin resistant Enterbacteriaceae. 
In per protocol analyses, we excluded women with 
protocol deviations, defined as women with no 
documented intake of at least one dose of study drug, 
crossovers, and women who used rescue antibiotics 
before day 3. These analyses were prespecified in a 
statistical analysis plan before the end of recruitment 
and inspection of the data.
In sensitivity analyses specified post hoc, we fitted 
mixed effects models with a random intercept for trial 
site and multivariable Poisson and linear regression 
models adjusted for baseline characteristics to estimate 
treatment effects. For the Poisson regression models we 
used robust sandwich estimators of standard errors.19 
We then transformed the resulting relative risks to risk 
differences by combining them with the control group 
risk in patients allocated to norfloxacin to ensure 
direct comparability with primary analyses. In further 
post hoc analyses of women allocated to diclofenac, 
we compared baseline characteristics and outcomes 
between those who used antibiotics until day 30 and 
those who never used antibiotics, determined the time 
between symptom onset and diagnosis in those with 
a clinical diagnosis of pyelonephritis, and explored 
whether blood or urine findings at baseline were 
associated with pyelonephritis with clinically relevant 
positive or negative likelihood ratios above 5 or below 
0.2, respectively, which could be used to rule in or 
rule out a future clinical diagnosis of pyelonephritis. 
All analyses were done in RStudio version 1.0.143 
(RStudio: Integrated Development for R. RStudio, 
Boston, MA www.rstudio.com/).
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, 
or implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. We 
plan to disseminate the results of the research to all the 
scientific community, including trial participants.
Results
Between 7 February 2012 and 3 December 2014, 253 
women were included in the trial. Thirty six patients 
were recruited in seven single practices, 108 in nine 
group practices, and 109 in one big medical centre 
with 17 doctors in the centre of Bern, Switzerland. 
One hundred and thirty three patients were randomly 
allocated to diclofenac and 120 to norfloxacin. A 
total of 125 women (94%) in the diclofenac group 
and 118 women (98%) in the norfloxacin group. 
received treatment as allocated. Follow-up until day 
30 was complete for 119 (89%) and 112 women 
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(93%), respectively (fig 1). Groups were similar 
(table 1), with a mean age of 36.8 years (SD 14.1), a 
mean duration of symptoms of 3.4 days (SD 2.7), and 
a mean composite symptom score of 13.7 points out 
of 30 (SD 4.0), and urgency, frequency, and dysuria 
as the most prevalent symptoms. Thirty five urine 
samples were positive for nitrite (14%) and 191 had 
more than ++ leucocytes (75%). Urinary cultures gave 
positive results for 185 urine samples (73%), resulting 
in a total of 193 isolates, of which 187 (97%) had 
documented norfloxacin susceptibility. In total, 173 
isolates contained Enterobacteriaceae, 160 of which 
were tested for fosfomycin susceptibility and 158 were 
found to be susceptible (99%).
Table 2 presents the clinical outcomes. The primary 
outcome, resolution of symptoms at day 3, was 
observed in 72 (54%) women in the diclofenac group 
and 96 (80%) in the norfloxacin group (risk difference 
27%, 95% confidence interval 15% to 38%, one 
sided P=0.98 for non-inferiority, two sided P<0.001 
for superiority in favour of norfloxacin group). The 
principal secondary outcome, use of any antibiotic 
Allocated to norfloxacin (n=120):
  Treated as allocated (n=118)
  Crossed over to NSAIDs (n=0)
  Did not take any antibiotics (n=2)
Allocated to diclofenac (n=133):
  Treated as allocated (n=125)
  Crossed over to antibiotics (n=8)
  Did not take any NSAIDs (n=0)
Patients randomised (n=253)
Follow-up data available for primary outcome
  (n=112)
  Lost to follow-up to day 3 (n=5)
  Followed up but missing data on primary
    outcome (n=3)
Follow-up data available for principle
  secondary outcome (n=115)
  Lost to follow-up to day 30 (n=5)
Follow-up data available for primary outcome
  (n=119)
  Lost to follow-up to day 3 (n=4)
  Followed up but missing data on primary
    outcome (n=10)
Follow-up data available for principle
  secondary outcome (n=129)
  Lost to follow-up to day 30 (n=4)
Analysed for primary outcome (n=120)
  With multiple imputation (n=8)
Analysed for principle secondary outcome
  (n=120)
  With multiple imputation (n=5)
Analysed for primary outcome (n=133)
  With multiple imputation (n=14)
Analysed for principle secondary outcome
  (n=133)
  With multiple imputation (n=4)
Fig 1 | Participant flow through study. NSAID=non-steroidal anti-inflammatory drug
Table 1 | Baseline characteristics of participants. Values are means (standard deviations) unless stated otherwise
Characteristics
Diclofenac group  
(n=133)
Norfloxacin group  
(n=120)
Age (years) 37.8 (14.2) 35.6 (14.0)
 No (%) aged <45 years 94 (71) 89 (74)
Symptom duration: days since UTI onset 3.6 (3.1) 3.2 (2.0)
 No (%) with symptom duration ≤3 days 80 (60) 83 (69)
No of UTIs in past 12 months 0.6 (1.1) 0.6 (0.9)
Baseline UTI symptoms (score 0-6):
 Dysuria 3.3 (1.3) 3.3 (1.2)
 Urgency 3.7 (1.0) 3.6 (0.9)
 Night frequency 2.6 (1.5) 2.6 (1.4)
 Day frequency 3.5 (0.9) 3.5 (0.9)
 Lower abdominal pain while urinating 2.6 (1.5) 2.6 (1.6)
 Back or loin pain 1.1 (1.4) 1.2 (1.5)
 Total symptom score 13.7 (3.9) 13.8 (3.8)
 No (%) with symptom score ≤20 127 (95) 115 (96)
Blood tests:
 C reactive protein (mg/L) 6.7 (10.5) 8.5 (13.7)
  No (%) with C reactive protein >10 mg/L 24 (18) 29 (24)
 Leucocytes (109/L) 8.5 (2.4) 8.7 (2.2)
Urinary dipstick:
 No (%) positive for nitrites 17 (13) 18 (15)
 Median (interquartile range) erythrocytes (+ to ++++) +++ (++ to ++++) +++ (++ to ++++)
 Median (interquartile range) leucocytes (+ to ++++) +++ (+++ to ++++) +++ (+++ to ++++)
 No (%) with leucocyte result >++ 101 (76) 90 (75)
Urinary culture (No (%))*:
 Negative 36 (27) 31 (26)
 Positive† 96 (72) 89 (74)
  Escherichia coli 82 (62) 75 (63)
  Other Enterobacteriaceae 10 (8) 6 (5)
  Staphylococcus saprophyticus 4 (3) 7 (6)
  Enterococcus faecalis 1 (1) 6 (5)
  βhaemolytic streptococcus group B 1 (1) 1 (1)
 Susceptibility to norfloxacin 92 (69) 87 (73)
  Enterobacteriaceae 88 (66) 79 (66)
 Susceptibility to fosfomycin‡ 84 (63) 71 (59)
UTI=urinary tract infection.
*Results missing in one patient in diclofenac group.
†Do not sum up owing to two double mixed infections in the diclofenac group and four double and one triple mixed infection in the norfloxacin group.
‡Relates to Enterobacteriaceae only. Two isolates from the diclofenac group (n=1 Proteus mirabilis, n=1 Enterobacter cloacae) were not susceptible to 
fosfomycin.
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up to day 30, was observed in 82 (62%) women in the 
diclofenac group and 118 (98%) in the norfloxacin 
group (risk difference 37%, 28% to 46%, P<0.001 
for superiority in favour of diclofenac group). Among 
the 82 women in the diclofenac group who used 
antibiotics, 58 (71%) decided to take antibiotics during 
the first three days; 55 of these 58 (95%) women took 
the rescue antibiotic fosfomycin. Supplementary table 
13 presents antibiotics taken in addition to the study 
drugs for any indication and for recurrent UTI. Five 
(4%) women in the diclofenac group and 13 (11%) in 
the norfloxacin group took additional analgesics up 
to day 3.
Figure 2 presents time to event curves for definite 
resolution of symptoms (top panel) and use of antibiotics 
(bottom panel) until day 10 (fig 2 and supplementary 
table 2). Supplementary figure 1 shows the course of 
symptom scores. The median time until resolution 
of symptoms was four days in the diclofenac group 
compared with two days in the norfloxacin group 
(hazard ratio 1.64, 95% confidence interval 1.26 to 
2.14, P<0.001). The median time until antibiotic use was 
five and zero days, respectively (10.06, 6.67 to 15.17, 
P<0.001). Figure 3 shows subgroup analyses for the 
primary and main secondary outcome. Results appeared 
consistent across all subgroups. Sensitivity analyses 
revealed consistent results for the primary and main 
secondary outcome (see supplementary tables 3-6).
The remaining prespecified outcomes favoured 
norfloxacin except for change in symptom score on day 
30 (P=0.88) and working days lost (P=0.18, table 2). 
Post hoc analyses of additional time points revealed 
little evidence of a difference between groups for 
resolution or complete absence of symptoms on days 
10 and 30 or change of symptom score on day 10 
(P≥0.07) and strong evidence for a difference in favour 
of the diclofenac group for antibiotic use up to day 3 
(P<0.001, table 2).
Supplementary table 7 shows a post hoc comparison 
of baseline characteristics of women who had never 
used antibiotics (n=51) with women who had used any 
antibiotics until day 30 (n=82) among those randomly 
allocated to diclofenac. We found little evidence for a 
difference between groups, except for one component 
of the symptom composite score. Supplementary table 
8 presents a comparison of outcomes. Resolution and 
complete absence of symptoms at day 3 were more 
common among women who never used antibiotics 
(P<0.01), changes of symptom scores were more 
pronounced at day 3 (P<0.01), reconsultations were 
less frequent (P<0.01), and scores on quality of life 
and satisfaction with care were higher (P<0.02). The 
median time to symptom resolution was three days 
in women who never used antibiotics and five days 
in women who used antibiotics (hazard ratio 0.61, 
95% confidence interval 0.42 to 0.88, P<0.01, see 
Table 2 | Primary and secondary outcomes. Values are numbers (percentages) unless stated otherwise
Outcomes
Diclofenac group 
(n=133)
Norfloxacin group 
(n=120)
Risk or mean difference 
(95% CI) P value
Resolution of symptoms:
 Day 3 (primary outcome) 72 (54) 96 (80) 27 (15 to 38) <0.001
 Day 7 111 (83) 115 (96) 12 (4 to 19) 0.003
 Day 10* 126 (95) 116 (97) 2 (−3 to 7) 0.45
 Day 30* 127 (95) 111 (93) −3 (−9 to 3) 0.32
Complete absence of symptoms:
 Day 3 10 (8) 20 (17) 9 (0 to 17) 0.038
 Day 7 44 (33) 65 (54) 21 (9 to 34) 0.001
 Day 10* 70 (53) 77 (64) 12 (−1 to 24) 0.07
 Day 30* 101 (76) 99 (83) 6 (−4 to 17) 0.22
Mean (SD) change of symptom score:
 Day 3 −7.3 (4.7) −10.3 (4.1) 3.0 (1.9 to 4.1) <0.001
 Day 7 −11.0 (4.8) −12.6 (4.2) 1.6 (0.5 to 2.7) 0.005
 Day 10* −12.2 (4.3) −12.9 (4.1) 0.7 (−0.4 to 1.7) 0.20
 Day 30 −13.0 (4.4) −13.1 (4.3) 0.1 (−1.0 to 1.1) 0.88
Use of any antibiotic:
 ≤day 3* 58 (44) 116 (97) −54 (−63 to −44) <0.001
 <day 30 (principal secondary outcome) 82 (62) 118 (98) −37 (−46 to −28) <0.001
Use of rescue antibiotic:
 ≤day 3 55 (41) 9 (8) 34 (24 to 43) <0.001
 <day 30* 73 (55) 18 (15) 40 (29 to 51) <0.001
Negative urinary culture at day 10 96 (72) 112 (93) 21 (11 to 30) <0.001
Reconsultations because of UTI (<day 30) 27 (20) 10 (8) 12 (3 to 20) 0.010
Mean (SD) quality of life (range 0-10):
 EuroQol health state (day 3) 8.8 (2.2) 9.4 (1.5) 0.6 (0.2 to 1.0) 0.005
 EuroQol visual analogue scale (day 3) 7.4 (1.9) 8.3 (1.5) 1.0 (0.5 to 1.4) <0.001
 Patient satisfaction with UTI management 5.7 (3.0) 8.2 (2.1) 2.5 (1.9 to 3.2) <0.001
 No of working days lost due to UTI 0.6 (0.8) 0.5 (0.8) 0.2 (−0.1 to 0.5)† 0.18
UTI=urinary tract infection; EuroQol=European quality of life instrument.
Positive differences favour norfloxacin, negative differences favour diclofenac.
*Analysis of additional time points, not prespecified in protocol.
†Relative rate increase calculated from Poisson regression.
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supplementary figure 2 and supplementary table  9). 
Thirty four urinary cultures had been positive at 
baseline among women who never used antibiotics, 
and the results for 16 of these spontaneously became 
negative on day 10 (47%).
Table 3 presents adverse events that resulted 
in reconsultations: 43 events in 41 women in the 
diclofenac group (31%) and 22 events in 21 women 
in the norfloxacin group (18%). Adverse events 
related to UTI were more common in the diclofenac 
group (P=0.01), with six cases of clinically diagnosed 
pyelonephritis in the diclofenac group (5%) and 
none in the norfloxacin group (P=0.03); one woman 
with clinically diagnosed pyelonephritis in the 
diclofenac group was classified to have experienced 
a serious adverse event as she was admitted to 
hospital to receive intravenous antibiotic treatment. 
Supplementary table 10 shows a comparison 
of baseline characteristics of women with and 
without pyelonephritis in the diclofenac group. 
Supplementary table 11 presents the timing of 
administered antibiotics since symptom onset and 
randomisation, and the type of antibiotic used in the 
six women with pyelonephritis. The median time from 
symptom onset to clinical diagnosis of pyelonephritis 
was 5.5 days (range 5.0-8.0 days). A post-hoc analysis 
revealed that C reactive protein levels >10 mg/L at 
baseline were observed in 21 women in the diclofenac 
group without pyelonephritis (17%) and in three 
women with pyelonephritis (50%, see supplementary 
table 10). This resulted in a positive likelihood ratio 
of 3.02 (95% confidence interval 1.07 to 5.98) for 
C reactive protein levels >10 mg/L. None of the 
remaining analysed characteristics was associated 
with statistically significant and clinically relevant 
positive or negative likelihood ratios suitable to rule 
in or rule out a future diagnosis of a pyelonephritis 
(see supplementary table 12). Supplementary table 
14 shows that mean symptom scores for women who 
developed pyelonephritis were higher at baseline 
and day 3 compared with women who did not 
develop pyelonephritis, but differences subsequently 
diminished. Supplementary figure 3 graphically 
shows the course of symptom scores in patients with 
and without pyelonephritis in the diclofenac group.
discussion
In this randomised, double blind trial in women with 
uncomplicated lower urinary tract infection (UTI), 
symptomatic treatment with the non-steroidal anti-
inflammatory drug (NSAID) diclofenac was inferior to 
antibiotic treatment with norfloxacin in controlling 
symptoms. Those treated with diclofenac were 27% 
less likely to have symptom resolution at day 3 after 
randomisation and 12% less likely to have symptom 
resolution at day 7 after randomisation, with higher 
mean symptom scores, more frequent reconsultations, 
a higher incidence of clinically diagnosed 
pyelonephritis, and lower patient satisfaction than 
those in the norfloxacin group. Conversely, women 
who received diclofenac were 37% less likely to receive 
antibiotics until day 30 after randomisation.
A meta-analysis of five trials concluded that 
antibiotics are clinically superior to placebo in 
women with uncomplicated lower UTI.18 Our trial, in 
conjunction with the recently published trial by Gágyor 
et al,10 suggests that antibiotics are also clinically 
superior to symptomatic treatment with NSAIDs. This 
contrasts with the findings of a small pilot trial by 
Bleidorn et al,9 where clinical outcomes of treatment 
with ibuprofen were similar to those of antibiotic 
treatment with ciprofloxacin. The pilot trial triggered 
both our trial and that by Gágyor et al.10 Both pivotal 
trials were adequately powered but failed to detect 
non-inferiority of NSAIDs compared with antibiotics 
for symptom control. Importantly, both trials suggest 
that symptomatic treatment with NSAIDs is associated 
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Fig 2 | Kaplan-Meier plot for (top panel) time until 
definite resolution of symptoms and (bottom panel) time 
until antibiotic use up to day 10. Nineteen women in the 
diclofenac group and nine in the norfloxacin group who 
reached the primary outcome definition of symptom 
resolution on day 3 subsequently reported a slight 
flare-up; they were considered to have experienced 
symptom resolution on day 3 (table 2), but reached 
definite symptoms later than day 3 (fig 2); six women 
in the diclofenac group and six in the norfloxacin group 
who reached the primary outcome definition of symptom 
resolution on day 3 did not provide enough information 
to derive the time point of definite resolution and were 
censored at day 0 (five in each group) or day 10 (one in 
each group)
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with an increase in the risk of clinically diagnosed 
pyelonephritis, which translates into a number needed 
to harm of 23 compared with antibiotic treatment in 
our trial. The risk of clinically diagnosed pyelonephritis 
in patients allocated to NSAIDs appeared higher than 
the risk observed in patients allocated to placebo in 
antibiotic trials by Christiaens et al and Ferry et al.20 
21 Although indirect comparisons like these should be 
interpreted with caution,22 they would be in line with 
recent evidence suggesting that NSAIDs may actually 
be harmful in patients with infectious diseases,23-25 
despite potential antibacterial activities of diclofenac26 
and ibuprofen.27 On the beneficial side, both pivotal 
trials suggest that antibiotic use can be halved on 
average by initial symptomatic treatment with NSAIDs, 
with a corresponding number needed to treat of 2 to 
prevent one instance of antibiotic use. We provided 
women with a rescue antibiotic for discretionary use 
after completion of the study drug and reaching the 
primary endpoint. This may have facilitated antibiotic 
use in the NSAID treatment arm of our trial. None 
the less, given the high global incidence of UTIs, the 
observed reduction in antibiotic use is highly relevant 
and is likely to immediately decrease resistance rates 
for Escherichia coli and even other microorganisms in 
the affected population.28
Resolution of symptoms at day 3
  Overall
  Age (years)
    <45
    ≥45
  Symptom score
    ≤20
    >20
  Symptom duration
    ≤3 days
    >3 days
  Urine culture
    Negative
    Positive
  Urine leucocytes*
    ≤++
    >++
  Documented norfloxacin-susceptible Enterobacteriaceae
    No
    Yes
Use of any antibiotic up to day 30
  Overall
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    <45
    ≥45
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    ≤20
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  Symptom duration
    ≤3 days
    >3 days
  Urine culture
    Negative
    Positive
  Urine leucocytes*
    ≤++
    >++
  Documented norfloxacin-susceptible Enterobacteriaceae
    No
    Yes
27 (15 to 38)
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36 (16 to 55)
26 (14 to 37)
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30 (17 to 43)
27 (7 to 47)
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-37 (-46 to -28)
-34 (-45 to -24)
-44 (-59 to -28)
-37 (-46 to -28)
-33 (-71 to 4)
-36 (-48 to -25)
-38 (-51 to -25)
-46 (-63 to -29)
-33 (-44 to -23)
-44 (-62 to -26)
-35 (-44 to -25)
-42 (-57 to -27)
-34 (-45 to -23)
0.39
0.36
0.86
0.84
0.37
0.84
0.38
0.82
0.89
0.25
0.38
0.45
-60 -30 0 30 60
Diclofenac better Norfloxacin better
Risk dierence (%)
(95% CI)
Risk dierence (%)
(95% CI)
P value for
interaction
72/133 (54)
52/94 (55)
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71/127 (56)
1/6 (17)
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21/36 (58)
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18/32 (56)
54/101 (53)
25/45 (56)
47/88 (53)
82/133 (62)
60/94 (64)
22/39 (56)
78/127 (61)
4/6 (67)
49/80 (61)
33/53 (62)
19/36 (53)
63/97 (65)
17/32 (53)
64/101 (63)
26/45 (58)
56/88 (64)
*Post hoc analysis
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96/120 (80)
69/89 (78)
27/31 (87)
93/115 (81)
3/5 (60)
66/83 (80)
30/37 (81)
28/31 (90)
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31/31 (100)
87/89 (98)
30/30 (100)
89/90 (99)
41/41 (100)
77/79 (97)
Norfloxacin
No of patients/total (%)
Fig 3 | Subgroup analyses of primary outcome (resolution of symptoms at day 3) and main secondary outcome. Positive differences favour 
norfloxacin, negative differences favour diclofenac
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The increasing antibiotic resistance among 
uropathogens in general and E coli (the most common 
uropathogen) in particular is a global concern. Many 
studies show a clear correlation between antibiotic 
consumption and rising resistance rates. Accordingly, 
antibiotics are often withheld in cases of self limited, 
benign bacterial diseases such as acute otitis media, 
sinusitis, and traveller’s diarrhoea at the cost of a 
prolongation of symptoms by typically 1-3 days.29-36 
Our results in women with uncomplicated lower UTI 
are well in line with the prolongation of symptoms 
observed with symptomatic treatment of these 
conditions. As many women in the diclofenac group 
resorted to antibiotic treatment in our trial, a strategy 
of selectively deferring rather than completely 
withholding antibiotic treatment may be preferable 
for uncomplicated lower UTI.37 This can be achieved 
through a shared decision making process, during 
which clinicians inquire about their patients’ ideas 
and expectations about antibiotic treatment for 
uncomplicated UTI and also explore the option of 
delaying antibiotic use as a treatment strategy.
Subgroup analyses did not provide evidence 
for any clinically relevant treatment by subgroup 
interactions. In particular, in contrast with the study 
by Gágyor et al,10 reduction in antibiotic prescription 
was comparable in women with and without positive 
urinary culture results. Testing initial urine samples 
for other biomarkers associated with UTI, such as 
heparin binding protein, interleukin 6, acetic acid, 
trimethylamine, xanthine oxidase, myeloperoxidase, or 
others,38-40 might have resulted in promising treatment 
by subgroup interactions, but these tests are not yet 
established in clinical practice, and we are unaware of 
any evidence to suggest that such interactions would 
be likely. In subgroup analyses, there were no relevant 
differences in baseline characteristics that would allow 
an early identification of women likely to benefit from 
diclofenac alone. However, in additional post hoc 
analyses, which were purely hypothesis generating, 
we found that the clinical diagnosis of pyelonephritis 
was established not earlier than five days after 
symptom onset, and that C reactive protein values 
>10 mg/L were more common at baseline in women 
who subsequently had a diagnosis of pyelonephritis. 
Taken together, these exploratory findings could 
support a tailored strategy of immediate antibiotic use 
in women with C reactive protein levels >10 mg/L and 
symptomatic treatment in remaining women for up to 
three or four days after symptom onset, followed by 
deferred, selective antibiotic use in those women who 
did not show a clear improvement by then. Naturally, 
such a tailored strategy would need to be evaluated in 
an appropriately powered randomised trial.
Strengths and limitations of this study
Our trial should be interpreted in view of its strengths 
and limitations. Strengths are its randomised 
double blind design with appropriate concealment 
of allocation; blinding of patients, therapists, and 
outcome assessors; the low loss to follow-up; the 
robustness of results in a series of sensitivity analyses; 
and the multicentre primary care setting. The premature 
termination of patient recruitment before reaching the 
initially planned sample size is an obvious limitation. 
However, the decision to stop recruitment was made 
without inspecting the data and is therefore unlikely 
to have biased our findings.41 Despite the smaller 
than originally planned sample size, our results are 
completely unequivocal. The self report questionnaire 
used to ascertain severity of symptoms was developed 
based on questionnaires described by Clayson et al12 
and Little et al,13 which were available at the time of 
designing our trial. Women had to rate the severity 
of dysuria, frequency, urgency, and abdominal pain 
when passing urine and pain or tenderness in the 
lower back or loin on Likert scales from 0 to 6. The 
resulting summary score from 0 to 30 used to assess 
symptom severity as one of the secondary outcomes 
was not psychometrically validated and should 
Table 3 | Adverse events resulting in reconsultations up to 30 days
Adverse events No (%) in diclofenac group (n=133) No (%) in norfloxacin group (n=120) Risk difference (95% CI) P value*
Related to UTI 26 (20) 10 (8) 11 (3 to 20) 0.012
 Persistent symptoms 16 (12) 4 (3) 9 (2 to 15) 0.011
 Additional symptoms 6 (5) 2 (2) 3 (−1 to 7) 0.29
 Recurrent UTI† 5 (4) 4 (3) 0 (−4 to 5) 1.00
 Pyelonephritis‡ 6 (5) 0 (0) 5 (1 to 8) 0.031
Other adverse event 17 (13) 12 (10) 3 (−5 to 11) 0.56
 Exanthema 1 (1) 2 (2) −1 (−4 to 2) 0.61
 Vaginitis 3 (2) 0 (0) 2 (0 to 5) 0.25
 Gastrointestinal symptoms§ 3 (2) 3 (3) −0 (−4 to 4) 1.00
Low back pain¶ 5 (4) 2 (2) 2 (−2 to 6) 0.45
Viral infection 1 (1) 3 (3) −2 (−5 to 1) 0.35
Trauma 3 (2) 1 (1) 1 (−2 to 4) 0.62
Miscellaneous** 3 (2) 1 (1) 1 (−2 to 4) 0.62
UTI=urinary tract infection.
Numbers do not add up as patients experienced at least one adverse event for each category.
*Two sided Fisher’s exact test.
†Recurrent UTI was defined as additional visits after day 14 because of recurrent UTI symptoms after symptoms had resolved by day 10, and the physician decided to treat with antibiotics.
‡One patient in the diclofenac group was admitted to hospital on day 4 because of pyelonephritis.
§Includes one case of diverticulitis in the norfloxacin group.
¶Considered to be of musculoskeletal origin by treating doctor.
**Includes one case of external otitis and two cases of tonsillitis in the diclofenac group and one case of hair loss in the norfloxacin group.
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therefore be considered exploratory. The primary 
outcome of symptom resolution at day 3 was defined as 
slight, very slight, or no problems reported for all five 
components.12 14 15 As these components assessed well 
established concepts and the calculation of a summary 
score was not necessary, we consider our primary 
outcome to be valid. A final limitation is that our 
results are not generalisable to countries and clinical 
settings with lower rates of susceptibility, which could 
decrease the effectiveness of antibiotics and render 
symptomatic treatment with NSAIDs less inferior.
Conclusions
Symptomatic treatment is inferior to antibiotic 
treatment for women with uncomplicated lower 
UTI in an ambulatory setting, as it increases median 
symptom duration by two days and is likely to 
be associated with an increased risk of clinically 
diagnosed pyelonephritis. The observed clinically 
relevant reduction in antibiotic use, which would 
likely contribute directly to decreasing resistance rates 
in the affected population, suggests that alternative 
approaches of combining symptomatic treatment with 
deferred, selective antibiotic use should be developed 
and tested in future trials.
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